AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.520
+0.070 (2.03%)
At close: Mar 9, 2026, 4:00 PM EDT
3.530
+0.010 (0.28%)
After-hours: Mar 9, 2026, 7:03 PM EDT
AbCellera Biologics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -146.41 | -162.86 | -146.4 | 158.52 | 153.46 | |
| Depreciation & Amortization | 28.82 | 65 | 30.89 | 24.7 | 17.25 | |
| Asset Writedown & Restructuring Costs | - | 32 | - | 8.4 | - | |
| Stock-Based Compensation | 55.79 | 67.58 | 64.18 | 49.48 | 30.65 | |
| Other Operating Activities | 1.2 | -84.44 | -5.78 | 6.43 | 1.55 | |
| Change in Accounts Receivable | -55.62 | -75.12 | -45.93 | 106.46 | 22.48 | |
| Change in Accounts Payable | 3.46 | 10.64 | -15.1 | -2.09 | -3.24 | |
| Change in Unearned Revenue | -5.83 | 26.04 | 25.55 | 15.45 | 39.34 | |
| Change in Income Taxes | -29.84 | 6.65 | 30.46 | -88.61 | -13.53 | |
| Change in Other Net Operating Assets | 17.15 | 5.95 | 18.25 | -1.38 | -3.38 | |
| Operating Cash Flow | -131.3 | -108.56 | -43.88 | 277.36 | 244.58 | |
| Operating Cash Flow Growth | - | - | - | 13.40% | 977.94% | |
| Capital Expenditures | -42.77 | -78.4 | -76.95 | -70.66 | -58.45 | |
| Cash Acquisitions | - | - | - | - | -11.46 | |
| Sale (Purchase) of Intangibles | - | - | - | -2 | - | |
| Investment in Securities | 75.91 | 164.1 | -169.47 | -296.4 | -294.96 | |
| Other Investing Activities | 54.61 | 35.71 | 25.31 | 16.43 | 32.62 | |
| Investing Cash Flow | 87.75 | 121.41 | -221.11 | -352.63 | -332.25 | |
| Long-Term Debt Issued | 29.73 | 13.5 | 11.59 | 2.76 | 5.49 | |
| Total Debt Issued | 29.73 | 13.5 | 11.59 | 2.76 | 5.49 | |
| Net Debt Issued (Repaid) | 29.73 | 13.5 | 11.59 | 2.76 | 5.49 | |
| Other Financing Activities | -15.65 | -0.73 | -1.23 | -4.38 | -9.37 | |
| Financing Cash Flow | 14.08 | 12.77 | 10.36 | -1.63 | -3.89 | |
| Foreign Exchange Rate Adjustments | 1.1 | -2.62 | 0.59 | -9.6 | -1.43 | |
| Net Cash Flow | -28.37 | 23.01 | -254.04 | -86.49 | -92.97 | |
| Free Cash Flow | -174.07 | -186.95 | -120.82 | 206.7 | 186.13 | |
| Free Cash Flow Growth | - | - | - | 11.05% | 1329.91% | |
| Free Cash Flow Margin | -231.69% | -648.40% | -317.75% | 42.58% | 49.61% | |
| Free Cash Flow Per Share | -0.58 | -0.64 | -0.42 | 0.66 | 0.58 | |
| Levered Free Cash Flow | -176 | -177.77 | -102.4 | 205.62 | 143.8 | |
| Unlevered Free Cash Flow | -176 | -177.77 | -102.4 | 205.62 | 143.8 | |
| Change in Working Capital | -70.69 | -25.84 | 13.23 | 29.83 | 41.67 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.